UnitedHealth: Everyone Is Overreacting

Despite missing Q2 2025 earnings expectations, I see potential in the company's valuation for future growth and profitability. I approach the analysis from a more abstract perspective, focusing on what current valuation implies for required growth. Within our analysis the company could currently be undervalued by up to 135%.